$180 Million is the total value of Foresite Capital Management IV, LLC's 7 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PHVS | Pharvaris N.V. | $78,125,802 | +37.8% | 3,743,450 | 0.0% | 43.39% | +55.7% | |
| CBAY | Cymabay Therapeutics, Inc. | $26,645,572 | +36.2% | 1,787,094 | 0.0% | 14.80% | +53.8% | |
| ACRS | Aclaris Therapeutics, Inc. | $19,235,033 | -33.9% | 2,808,034 | 0.0% | 10.68% | -25.4% | |
| KURA | Kura Oncology, Inc. | $16,871,517 | -13.8% | 1,849,947 | 0.0% | 9.37% | -2.6% | |
| KNTE | Kinnate Biopharma Inc. | $13,540,300 | -53.8% | 9,671,643 | 0.0% | 7.52% | -47.8% | |
| LYEL | Sell | Lyell Immunopharma, Inc. | $12,913,675 | -58.1% | 8,784,813 | -9.4% | 7.17% | -52.7% |
| SNDX | Syndax Pharmaceuticals, Inc. | $12,705,000 | -30.6% | 875,000 | 0.0% | 7.06% | -21.6% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CymaBay Therapeutics, Inc. | 23 | Q3 2023 | 14.8% |
| Aclaris Therapeutics, Inc. | 18 | Q3 2023 | 18.9% |
| Kura Oncology, Inc. | 16 | Q3 2023 | 11.7% |
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 41.8% |
| Myokardia, Inc. | 12 | Q3 2020 | 17.8% |
| Pharvaris N.V. | 11 | Q3 2023 | 43.4% |
| Cytokinetics Incorporated | 11 | Q2 2021 | 31.6% |
| Lyell Immunopharma, Inc. | 10 | Q3 2023 | 29.2% |
| Insmed Incorporated | 10 | Q1 2020 | 19.2% |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | Q1 2020 | 14.5% |
View Foresite Capital Management IV, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-02-22 |
| 13F-HR | 2023-02-13 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-12 |
View Foresite Capital Management IV, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.